FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2451-2453 June 9, 2005 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kurzrock, R. Related Article by Horstmann, E. PubMed Citation

To the Editor: Horstmann et al. (March 3 issue)¹ assume that a tumor response is of benefit to subjects in phase 1 oncology trials. This assumption is not valid. A complete or partial tumor response in a phase 1 trial is a surrogate end point, which for most agents has not been linked to a clinically meaningful outcome, such as improved survival.²

Informing subjects that they have a 10.6 percent chance of a tumor response is potentially misleading unless accompanied by an explicit discussion of clinical end points and whether any connection exists between a tumor response and clinical end . . . [Full Text of this Article]

This article has been cited by other articles:

• Dresser, R. (2009). First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless.. J Law Med Ethics 37: 38-50  
• Italiano, A., Massard, C., Bahleda, R., Vataire, A.-L., Deutsch, E., Magne, N., Pignon, J.-P., Vassal, G., Armand, J.-P., Soria, J.-C. (2008). Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19: 787-792 [Abstract] [Full Text]  
• Kumar, A., Soares, H., Wells, R., Clarke, M., Hozo, I., Bleyer, A., Reaman, G., Chalmers, I., Djulbegovic, B. (2005). Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ 331: 1295- [Abstract] [Full Text]